Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113971 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTMPI | |
| SCHEMBL2113972 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTMPI | |
| SCHEMBL2113976 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTMPI | |
| SCHEMBL713698 | 0.81 | GAA (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL713697 | 0.81 | GAA (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL713696 | 0.81 | GAA (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL713699 | 0.81 | GAA (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17600984 | 0.79 | CYP1A2 (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17600985 | 0.79 | CYP1A2 (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30296302 | 0.76 | KDM4E (0.30) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KDM4E 3834/4885MEN1 3999/4885ALDH1A1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.